Bristol Myers Squibb said it is disappointed with the outcome of a study that examined whether one of its drugs could be used to treat a certain type of skin cancer.
The drug, Opdualag, didn't meet its primary endpoint of recurrence-free survival when used as an additional treatment for patients with completely resected stage III-IV melanoma.
Vice President Jeffrey Walch, Opdualag global program lead, said Thursday that patients whose tumors are completely resected, or surgically removed, may not have enough antitumor T cells left for the drug to have its maximal effect.
"Opdualag remains a standard of care in the first-line treatment of unresectable or metastatic melanoma," he said, "and we continue to explore its potential across tumor types, including in non-small cell lung cancer."
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.